Armed with results from a phase 2 trial, Boehringer Ingelheim has said it will take its obesity drug candidate survodutide into a phase 3 programme later this year. The glucagon/GLP-1 receptor dual ...
Abstract: The crucial issue in current methods for skeleton-based action recognition: how to comprehensively capture the evolving features of global context information and temporal dynamics, and how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results